Abstract
ObjectiveTo determine whether tirofiban can prevent microcirculation dysfunction during delayed percutaneous coronary intervention (PCI) of spontaneously recanalized and severe narrowing coronary artery in patients with acute myocardial infarction. Methods62 patients who have a single angiographically confirmed narrowing culprit coronary artery for more than 75% between 7 and 14days after the onset of acute myocardial infarction were randomly divided into the tirofiban group (32 cases) and the placebo group (30 cases). All the patients received measurement of the index of microcirculatory resistance (IMR) before tirofiban/placebo administration and PCI. After PCI, IMR value was measured again. ResultsThere was no significant variation between the two groups before PCI (11.67±6.45 of placebo group vs. 14.65±12.45 of tirofiban group, P=0.158). After PCI, the IMR value of the tirofiban group is significantly lower than that of the placebo group (23.63±9.91 of placebo group vs. 16.75±9.98 of tirofiban group, P=0.008). ConclusionsIntracoronary injection of tirofiban can significantly prevent the abnormal increase of IMR value during delayed PCI in patients with acute myocardial infarction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
